Core Viewpoint - The launch of the long-acting methylphenidate sustained-release tablets by Hefei Lifan Pharmaceutical Co., Ltd. marks a significant development in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China, with the potential to capture a substantial market share due to existing supply constraints from imported alternatives [1][4]. Group 1: Product Launch and Market Context - Hefei Lifan Pharmaceutical announced the official launch of its methylphenidate sustained-release tablets for ADHD on September 2, following approval from the National Medical Products Administration on April 14 [1][3]. - The global ADHD medication market was valued at $14.31 billion in 2023 and is projected to reach $18.6 billion by 2030, with a compound annual growth rate (CAGR) of 3.69% [1][3]. - Prior to Lifan's launch, the only approved long-acting methylphenidate product in China was from Johnson & Johnson, which has faced supply constraints due to increased global demand [4][5]. Group 2: Sales Performance and Market Share - Sales of Lifan's methylphenidate sustained-release tablets in domestic sample hospitals were approximately 350 million yuan in 2023, with an expected increase to about 430 million yuan in the first three quarters of 2024 [1][3]. - Analysts predict that Lifan's product could capture around 15% of the market share in its first year of sales, addressing the supply gap left by the imported product [4]. Group 3: Regulatory and Production Considerations - The production and distribution of methylphenidate sustained-release tablets are subject to strict regulatory controls, requiring approval from the National Medical Products Administration [5]. - Lifan has established an integrated supply system for the active pharmaceutical ingredient and the formulation, which is crucial for maintaining consistent supply and quality [5].

Core Viewpoint - The launch of the domestic version of methylphenidate extended-release tablets by Hefei Lifan Pharmaceutical Co., Ltd. addresses the supply shortage of ADHD treatment in China, tapping into a significant market potential for ADHD medications [1][3][4]. Group 1: Product Launch and Market Context - Hefei Lifan Pharmaceutical announced the official launch of its methylphenidate extended-release tablets for ADHD treatment on September 2 [1]. - The product received approval from the National Medical Products Administration in April 2023, marking it as the first domestic generic version of this medication [3]. - The ADHD medication market is projected to grow from $14.31 billion in 2023 to $18.6 billion by 2030, with a compound annual growth rate of 3.69% [4]. Group 2: Market Demand and Supply Dynamics - The prevalence of ADHD in adults in China is approximately 3%, while the prevalence in children is around 6.26%, indicating a large potential patient base [3]. - The only previously approved long-acting methylphenidate product in China was from Johnson & Johnson, which has faced supply challenges due to increased global demand [4][5]. - The sales of methylphenidate extended-release tablets in domestic hospitals were approximately 350 million yuan in 2023, with an expected increase to about 430 million yuan in the first three quarters of 2024 [5]. Group 3: Competitive Landscape and Future Outlook - With the launch of Lifan Pharmaceutical's product, it is anticipated to capture around 15% of the market share in its first year [5]. - The company utilizes advanced three-layer osmotic pump controlled-release technology for its product, ensuring effective and stable therapeutic effects [6]. - The production and distribution of the medication are subject to strict regulatory controls due to its classification as a first-class psychotropic drug [6].